StockMarketWire.com - Pharmaceutical company GlaxoSmithKline said the US Food and Drug Administration had approved its a drug used to treat blood cancer patients.
The drug, BLENREP, was approved as s a monotherapy treatment for adult patients with 'relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory agent,' the company said.
'Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials,' it added.
This approval marked the second FDA approval for GSK's oncology portfolio in four months.
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.